Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: An overview of neuropathic pain PART 06: Market landscape • Market overview • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by indication • Diabetic neuropathy • Chemotherapy-induced neuropathy pain • Postherpetic neuralgia • Others PART 09: Market segmentation by drug class • Calcium channel alpha 2-delta ligands • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • TCAs • Opioid analgesics • Others PART 10: Geographical segmentation • Neuropathy pain treatment market in Americas • Neuropathy pain treatment market in EMEA • Neuropathy pain treatment market in APAC PART 11: Decision framework PART 12: Drivers and challenges • Market drivers • Impact of drivers on key customer segments • Market challenges • Impact of challenges on key customer segments PART 13: Market trends • Development of topical patches for the treatment of neuropathic pain likely to change market dynamics • Growing focus on emerging economies • Increasing mergers and acquisitions would lead to further consolidation PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • Depomed • Eli Lilly • Endo International • Pfizer • Other prominent vendors PART 16: Appendix • List of abbreviations List of Exhibits Exhibit 01: Global neuropathy pain treatment market snapshot Exhibit 02: Global neuropathic pain treatment market 2016-2021 ($ millions) Exhibit 03: Opportunity analysis in global neuropathy pain treatment market Exhibit 04: Five forces analysis Exhibit 05: Key pipeline candidates by indication Exhibit 06: Pipeline analysis Exhibit 07: Global neuropathy pain treatment market segmentation by indication 2016 Exhibit 08: Global diabetic neuropathy market 2016-2021 ($ millions) Exhibit 09: Global chemotherapy-induced neuropathic pain drugs market 2016-2021 ($ millions) Exhibit 10: Global postherpetic neuralgia drugs market 2016-2021 ($ millions) Exhibit 11: Global other neuropathy pain drugs market 2016-2021 ($ millions) Exhibit 12: Neuropathy pain market by drug class 2016 Exhibit 13: Segmentation of global neuropathy pain treatment market based on geography 2016 and 2021 Exhibit 14: Neuropathy pain treatment market revenue by geography 2016-2021 ($ millions) Exhibit 15: Market scenario in Americas Exhibit 16: Neuropathic pain treatment market in Americas 2016-2021 ($ millions) Exhibit 17: Market scenario in EMEA Exhibit 18: Neuropathy pain treatment market in EMEA 2016-2021 ($ millions) Exhibit 19: Market scenario in APAC Exhibit 20: Neuropathic pain treatment market in APAC 2016-2021 ($ millions) Exhibit 21: Impact of drivers Exhibit 22: Impact of challenges Exhibit 23: Competitive structure analysis of global neuropathic pain treatment market 2016 Exhibit 24: Competitive analysis of global neuropathic pain treatment market Exhibit 25: Strategic success factors of companies in global neuropathic pain treatment market Exhibit 26: Depomed: Key highlights Exhibit 27: Depomed: Strength assessment Exhibit 28: Depomed: Strategy assessment Exhibit 29: Depomed: Opportunity assessment Exhibit 30: Eli Lilly: Key highlights Exhibit 31: Eli Lilly: Strength assessment Exhibit 32: Eli Lilly: Strategy assessment Exhibit 33: Eli Lilly: Opportunity assessment Exhibit 34: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions) Exhibit 35: Endo International: Key highlights Exhibit 36: Endo International: Strength assessment Exhibit 37: Endo International: Strategy assessment Exhibit 38: Endo International: Opportunity assessment Exhibit 39: Endo International: YoY and growth rate of LIDODERM (branded) 2013-2015 ($ millions) Exhibit 40: Pfizer: Key highlights Exhibit 41: Pfizer: Strength assessment Exhibit 42: Pfizer: Strategy assessment Exhibit 43: Pfizer: Opportunity assessment Exhibit 44: Pfizer: YoY and growth rate of LYRICA 2013-2015 ($ millions) Exhibit 45: Pfizer: YoY and growth rate of NEURONTIN 2013-2015 ($ millions)

Depomed, Eli Lilly, Endo International, Pfizer, Allodynic Therapeutics, Arbor Pharmaceuticals, Astellas Pharma, Aurobindo Pharma, Avanir Pharmaceuticals, Biogen, CAPNIA, Centrexion Therapeutics, Cerecor, ContraVir Pharmaceuticals, Crescita Therapeutics, DAEWOONG, Daiichi Sankyo, Dr. Reddy's Laboratories, Eisai Pharmaceuticals, Grünenthal, GlaxoSmithKline, Hydra Biosciences, Immune Pharmaceuticals, Jiangsu Hengrui Medicine, Lexicon Pharmaceuticals, Lupin, Mallinckrodt, Midatech Pharma, Neurotune, Newron Pharmaceuticals, Novaremed, Novartis, PledPharma, Premier Biomedical, Regeneron, Samyang Biopharmaceuticals, Sienna Biopharmaceuticals, Sun Pharma, Teva Pharmaceutical Industries, TheraVasc, TORAY INDUSTRIES, Torrent Pharmaceuticals, UCB Pharma, VanWorld Pharmaceutical (a subsidiary of Vanway), VistaGen Therapeutics, WEX Pharmaceuticals, WINSTON PHARMACEUTICALS, Wockhardt, and Yuhan Corporation.